ANI (ANIP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - ANI Pharmaceuticals reported $137.43 million in revenue for Q1 2024, a year-over-year increase of 28.7% [1] - The EPS for the same period was $1.21, compared to $1.17 a year ago, indicating a positive trend [1] - The revenue exceeded the Zacks Consensus Estimate of $125.01 million by 9.94%, and the EPS surpassed the consensus estimate of $0.98 by 23.47% [1] Revenue Breakdown - Net revenues from generic pharmaceutical products were $70.22 million, exceeding the estimated $67.81 million, reflecting a 10.2% year-over-year increase [2] - Total net revenues from generics, established brands, and other segments reached $100.49 million, compared to the estimated $87.32 million [2] - Net revenues from rare disease pharmaceutical products were $36.94 million, slightly below the estimated $37.69 million, but still showing a significant year-over-year increase of 126.2% [2] - Established brand pharmaceutical products, royalties, and other services generated $30.28 million, surpassing the estimated $19.51 million [2] Stock Performance - ANI's shares have returned -3.3% over the past month, while the Zacks S&P 500 composite increased by 0.2% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]